Amplify Weight Loss Drug & Treatment ETF (THNR)
| Assets | $5.61M |
| Expense Ratio | 0.59% |
| PE Ratio | 20.88 |
| Forward PE | 16.47 |
| Shares Out | 230,000 |
| Dividend | $0.41 (1.67%) |
| Ex-Dividend Date | Dec 30, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 64.06% |
| Volume | n/a |
| Open | n/a |
| Previous Close | 24.17 |
| Day's Range | n/a |
| 52-Week Low | 22.89 |
| 52-Week High | 27.94 |
| Beta | 0.43 |
| Holdings | 23 |
| Inception Date | May 21, 2024 |
About THNR
Fund Home PageThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Top 10 Holdings
63.63% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 10.62% |
| Novo Nordisk A/S | NVO | 8.84% |
| Amgen Inc. | AMGN | 5.89% |
| AbbVie Inc. | ABBV | 5.71% |
| Pfizer Inc. | PFE | 5.60% |
| Roche Holding AG | ROP | 5.54% |
| CSPC Pharmaceutical Group Limited | 1093 | 5.48% |
| Gilead Sciences, Inc. | GILD | 5.42% |
| AstraZeneca PLC | AZN | 5.33% |
| Merck & Co., Inc. | MRK | 5.21% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.41317 | Dec 31, 2025 |
| Dec 30, 2024 | $0.2199 | Dec 31, 2024 |
Performance
THNR had a total return of 4.41% in the past year, including dividends. Since the fund's inception, the average annual return has been -1.05%.
News
From Laggard to Leader: The Surprising Comeback of Healthcare
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's mo...
Who Are You Calling Passive? Many Index ETFs Dynamically Rebalanced in September
There is a myth that index-based ETFs are all static buy-and-hold products that passively track a benchmark. Many people think of indexing through the lens of market-cap strategies like the Vanguard S...
NTHM's Index Rebalance Puts Thematic Rotation to Work
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP...
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead
The Amplify Weight Loss Drug & Treatment ETF (THNR) just refreshed its holdings to keep pace with where the weight-loss drug race is heading. Its underlying index, the VettaFi Weight Loss Drug & Treat...
SILJ, HACK, THNR: Trends in Thematic Investing
Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.